Exploring the Value of Theragnostic Radionuclide Therapies
Within Advanced Oncology
The 3rd Digital Targeted Radiopharmaceuticals (TRP) Summit returns at a crucial time for the entire industry. Spurred on by positive Phase III VISION trial data, there has been huge research investment, on both sides of the Atlantic, on how to deliver radiation therapy directly and specifically to tumours.
Hear the latest insights, case studies and novel data to help accelerate the development of next-generation radioligand therapies from clinical approval to commercialisation.
This is the only industry-led platform to bring the discussion around the challenges and opportunities facing developers of theranostic radioligand therapies.
Strive to tackle topics that are on every drug developer’s mind:
- How do we identify and validate new targets?
- Can we combine targeted radiopharmaceuticals with immunotherapy or other targeted oncology methods?
- How do we improve current clinical design methodologies and patient selection strategies?
- Where can improvements be made to the current supply and fulfillment models?
To see the wide variety of talks, panels and speakers tackling these issues, download the full event guide here